Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

[1]  G. Arpino,et al.  An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study , 2013, ClinicoEconomics and outcomes research : CEOR.

[2]  W. Gradishar,et al.  nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis , 2013, Breast Cancer Research and Treatment.

[3]  E. Winer,et al.  CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Gradishar,et al.  Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Iwase,et al.  Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval , 2011, OncoTargets and therapy.

[6]  Maria Aparecida Nagai,et al.  Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients , 2011, Breast Cancer Research and Treatment.

[7]  H. Rugo,et al.  SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). , 2010 .

[8]  K. Blackwell,et al.  SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). , 2010 .

[9]  W. Gradishar,et al.  Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Scott E McNeil,et al.  Nanoparticle therapeutics: a personal perspective. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[11]  W. Gradishar,et al.  Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status , 2008, Anti-cancer drugs.

[12]  M. Aapro,et al.  Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer , 2008 .

[13]  Neil Desai,et al.  Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel , 2008, Clinical Cancer Research.

[14]  Andrea S. Llera,et al.  The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.

[15]  N. Robert,et al.  Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. , 2007, Clinical breast cancer.

[16]  E. Rowinsky,et al.  Novel agents that target tublin and related elements. , 2006, Seminars in oncology.

[17]  M. Delano,et al.  Emerging implications of nanotechnology on cancer diagnostics and therapeutics , 2006, Cancer.

[18]  Neil Desai,et al.  Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Brian Samuels,et al.  Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Soon-Shiong,et al.  SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol , 2005 .

[22]  G. Watkins,et al.  Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[23]  P. Parsons,et al.  Novel markers for poor prognosis in head and neck cancer , 2005, International journal of cancer.

[24]  D. Berry,et al.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[26]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[27]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Patrick Soon-Shiong,et al.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[30]  J. Verweij,et al.  Measurement of fraction unbound paclitaxel in human plasma. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[31]  J. Beijnen,et al.  Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients , 1999, British Journal of Cancer.

[32]  C. Kearns.  Pharmacokinetics of the Taxanes , 1997, Pharmacotherapy.

[33]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Brekken,et al.  SPARC, a matricellular protein: at the crossroads of cell-matrix communication. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[35]  K. Mross,et al.  The pharmacokinetics of a 1-h paclitaxel infusion , 2000, Cancer Chemotherapy and Pharmacology.

[36]  A. Bershadsky,et al.  Microtubule dynamics: mechanism, regulation, and function. , 1991, Annual review of cell biology.